Alvotech (NASDAQ:ALVOW) Short Interest Up 39.3% in November

Alvotech (NASDAQ:ALVOW) was the target of a significant increase in short interest in the month of November. As of November 30th, there was short interest totalling 25,500 shares, an increase of 39.3% from the November 15th total of 18,300 shares. Based on an average daily trading volume, of 3,800 shares, the short-interest ratio is currently 6.7 days.

Alvotech Trading Up 9.8 %

Shares of NASDAQ:ALVOW traded up $0.25 on Friday, hitting $2.80. 855 shares of the company’s stock were exchanged, compared to its average volume of 8,012. Alvotech has a 1-year low of $1.71 and a 1-year high of $6.31. The firm’s 50-day moving average is $2.95 and its 200 day moving average is $2.91.

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass.